We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current 50UC market cap is 166.1B. The company's latest EPS is USD 4.5382 and P/E is 25.81.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 26.62B | 37.42B | 44.35B | 45.81B | 54.07B |
| Operating Income | 4.08B | -293M | 3.54B | 7.89B | 9.91B |
| Net Income | 3.2B | 112M | 3.29B | 5.96B | 7.04B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 66.73B | 105.36B | 96.48B | 101.12B | 104.04B |
| Total Liabilities | 51.09B | 66.08B | 59.43B | 61.95B | 63.16B |
| Total Equity | 15.64B | 39.29B | 37.06B | 39.17B | 40.87B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 4.8B | 5.96B | 9.81B | 10.35B | 11.86B |
| Investing | -285M | -11.06B | -2.96B | -4.06B | -7.98B |
| Financing | -2.2B | 3.65B | -6.82B | -6.57B | -4B |
| Market Cap | 166.1B |
| Price to Earnings Ratio | 25.81 |
| Price to Sales Ratio | 3.36 |
| Price to Cash Ratio | 33.09 |
| Price to Book Ratio | 4.44 |
| Dividend Yield | - |
| Shares Outstanding | 1.55B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 4.9 (4.47%) |
| Company Name | Astrazeneca 31 |
| Address |
1 francis crick avenue cambridge CB2 0AA |
| Website | https://www.astrazeneca.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
